A Deep Dive into Cardiac Resynchronization Therapy Market 2025: Key Drivers, Growth Factors, and Projections 2025-2034

What Are the Market Size and Growth Forecast for the Cardiac Resynchronization Therapy Market?
In recent times, the market size for cardiac resynchronization therapy has seen significant expansion. The market is predicted to rise from $6.29 billion in 2024 to $6.74 billion in 2025, showcasing a compound annual growth rate (CAGR) of 7.2%. The notable growth during the historical period is due to factors like an aging population, a surge in cases of heart failure, an increase in R&D investments for creating innovative CRT devices, broader knowledge of the advantages of the therapy, programs training physicians, and a dynamic competitive scene.

Robust expansion is anticipated in the cardiac resynchronization therapy market over the upcoming years, with projections placing it at approximately $8.77 billion by 2029, and a compound annual growth rate (CAGR) of 6.8%. This projected advancement can be credited to factors such as rise in heart failures and cardiac ailments, growth of the elderly population, an increased occurrence of cardiovascular diseases, a growing requirement for CRT therapy, enhancements in pacemaker and defibrillator treatments, and heightened awareness about CRT therapy. Significant emerging trends during the forecast period encompass the preference for CRT-D devices over traditional pacemakers, the implementation of advanced technology, the broadening scope of CRT therapy, adoption of artificial intelligence and machine learning.

What Is Driving the Growth Trajectory of the Cardiac Resynchronization Therapy Market?
The cardiac resynchronization therapy market is anticipated to grow due to the rising prevalence of cardiovascular illnesses. Cardiovascular diseases (CVD) which involve conditions affecting the heart and blood vessels, are on the rise due to various factors such as an aging population, unhealthy living habits, increased tobacco usage, sedentary behaviors, and poor diets. Cardiac resynchronization therapy (CRT), which enhances the heart's contractions through synchronized electrical impulses, aids in the treatment of cardiovascular diseases like heart failure. For instance, based on data from the Minnesota Department of Health published in September 2024, about 30% of Minnesota adults had high blood pressure in 2023, amounting to nearly 1.4 million individuals. In 2022, hypertensive diseases contributed to the death of 14,225 residents, accounting for almost 28% of all deaths in the state. Hence, the increase in cardiovascular diseases propels the growth of the cardiac resynchronization therapy market. With respect to the cardiac resynchronization therapy market, another driving force is the escalating healthcare expenditure. Healthcare expenditure represents the total funds expended on health-related goods and services within a given time, usually at a national or institutional level. By investing in healthcare, research and development in cardiac resynchronization therapy can be supported, leading to technological advancement, better access to therapy, and a more holistic outlook on individual health and healthcare systems. For instance, according to the UK's Office for National Statistics from May 2023, there was a nominal increase of 9.4% and a practical increase of 9.7% in UK's healthcare spending. The total healthcare expenditure in the UK in 2021 was $367.25 billion (£280.7 billion), pharmaceutical expenses amounted to $51.84 billion (£39.6 billion), and spending on preventative care significantly increased in 2021, hitting $45.93 billion (£35.1 billion). Moreover, in September 2024 as reported by Cross River Therapy, a US-based provider of ABA therapy services, the U.S. pharmaceutical industry had a revenue of $550 billion, while the spending on medicine by Americans in 2021 was $576.9 billion and is projected to escalate to $605-$635 billion by 2025. Consequently, the rise in healthcare expenditure stimulates the growth of the cardiac resynchronization therapy market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15531&type=smp

Which Key Market Leaders Are Driving Cardiac Resynchronization Therapy Industry Growth?
Major companies operating in the cardiac resynchronization therapy market are Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Terumo Corporation, Biotronik SE & Co. KG, Lepu Medical Technology (Beijing) Co. Ltd., Integer Holdings Corporation, Merit Medical Systems Inc., LivaNova PLC, MicroPort Scientific Corporation, Sorin Group, Berlin Heart GmbH, EBR Systems Inc., Corvia Medical Inc., Recor Medical, Jarvik Heart Inc., Cardiac Dimensions Inc., Farapulse Inc., Osypka Medical GmbH, Japan Medical Device Corporation, Imricor Medical Systems Inc., Vascular Dynamics Inc., Svelte Medical Systems, Aleva Neurotherapeutics, BioSig Technologies Inc.

What Are the Emerging Trends in the Cardiac Resynchronization Therapy Industry?
Major businesses involved in the cardiac resynchronization therapy (CRT) market are concentrating their efforts on the development of implantable devices, aiming to enhance the success of treatments for those suffering from heart failure. These implantable devices utilized in CRT work by synchronizing the ventricles' contractions in the heart, increasing the effectiveness of pumping and controlling the symptoms of heart failure. For example, in February 2024, the China-based medical device firm, MicroPort Scientific Corporation, introduced the GALI SonR cardiac resynchronization therapy and defibrillation device (CRT-D) along with the Navigo 4LV left ventricular pacing leads in Japan. This is recognized as the first and single CRT hemodynamic sensor engineered to carry out automatic optimization of patients on a weekly basis and importantly, during patient's active periods for effective real-time optimization. The clinically validated SonR algorithm is able to reduce the risk of hospitalization due to heart failure by 35%, and it also plays a key role in maintaining the health and safety of patients with CRT-D.

What Are the Main Segments in the Cardiac Resynchronization Therapy Market?
The cardiac resynchronization therapy market covered in this report is segmented -

1) By Type: Cardiac Resynchronization Therapy (CRT)-Defibrillator, Cardiac Resynchronization Therapy (CRT)-Pacemaker
2) By Age: Below 44 Years, 45-64 Years, 65-84 Years, Above 85 Years
3) By End-Use: Hospitals, Cardiac Care Centers, Ambulatory Surgical Centers

Subsegments:
1) By Cardiac Resynchronization Therapy (CRT)-Defibrillator: Single-Chamber CRT-D, Dual-Chamber CRT-D, Triple-Chamber CRT-D, Bi-Ventricular CRT-D
2) By Cardiac Resynchronization Therapy (CRT)-Pacemaker: Single-Chamber CRT-P, Dual-Chamber CRT-P, Triple-Chamber CRT-P, Bi-Ventricular CRT-P

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/cardiac-resynchronization-therapy-global-market-report

Which Geographic Area Leads the Cardiac Resynchronization Therapy Market?
North America was the largest region in the cardiac resynchronization therapy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac resynchronization therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Cardiac Resynchronization Therapy Global Market Report?

- Market Size Analysis: Analyze the Cardiac Resynchronization Therapy Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Cardiac Resynchronization Therapy Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Cardiac Resynchronization Therapy Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Cardiac Resynchronization Therapy Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15531

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.